A2 Milk results set the stage for further growth

Peter Garnry

Head of Equity Strategy

On May 31, 2018, we issued a buy recommendation on a2 Milk, a fast-growing New Zealand dairy company, with a price target of AUD 15 against a market price at the time of AUD 9.93. Yesterday, the company released its FY'18 (ending June 30) results, showing 68% revenue growth and an EBITDA margin expanding to 30.7% up from 26.2% in FY'17. Free cash flow increased to AUD 228.6 million translating into a 2.8% free cash flow yield. This is not aggressive valuation given this is a high growth dairy company with a compelling story, expanding into China and South Korea on top of having zero gross debt on the balance sheet.

We maintain our positive view on the stock based on the FY'18 result.

Management says it anticipates further growth in FY'19 driven by Australia, New Zealand, China. and US markets. The company has a 34.7% return on invested capital against cost of capital at 13.4% translating into a healthy profitability spread for shareholders. A2 Milk will in our view continue to be an attractive long-term growth story in Asia in an interesting product category. The infant formula segment in particular is expected to grow quickly in China.

A2 Milk continues to have a high score in our Equity Radar model (+0.47) driven by very high quality (return on capital), zero leverage on the balance sheet, and very high momentum.

The risks are a stronger AUD, a weaker Chinese economy, research showing little healthy effects from a2 proteins in a2 milk, and lower operating margins from increased competition.
A2 Milk weekly share price since IPO (source: Saxo Bank)

Saxo Capital Markets (Australia) Pty Ltd prepares and distributes information/research produced within the Saxo Bank Group for informational purposes only. In addition to the disclaimer below, if any general advice is provided, such advice does not take into account your individual objectives, financial situation or needs. You should consider the appropriateness of trading any financial instrument as trading can result in losses that exceed your initial investment. Please refer to our Analysis Disclaimer, and our Combined Financial Services Guide and Product Disclosure Statement. All legal documentation and disclaimers can be found at https://www.home.saxo/en-au/legal/.

The Saxo Bank Group entities each provide execution-only service. Access and use of Saxo News & Research and any Saxo Bank Group website are subject to (i) the Terms of Use; (ii) the full Disclaimer; and (iii) the Risk Warning in addition (where relevant) to the terms governing the use of the website of a member of the Saxo Bank Group.

Saxo News & Research is provided for informational purposes, does not contain (and should not be construed as containing) financial, investment, tax or trading advice or advice of any sort offered, recommended or endorsed by Saxo Bank Group and should not be construed as a record of our trading prices, or as an offer, incentive or solicitation for the subscription, sale or purchase in any financial instrument. No representation or warranty is given as to the accuracy or completeness of this information. All trading or investments you make must be pursuant to your own unprompted and informed self-directed decision. No Saxo Bank Group entity shall be liable for any losses that you may sustain as a result of any investment decision made in reliance on information on Saxo News & Research.

To the extent that any content is construed as investment research, such content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, would be considered as a marketing communication.

Please read our disclaimers:
- Full Disclaimer (https://www.home.saxo/en-au/legal/disclaimer/saxo-disclaimer)
- Analysis Disclaimer (https://www.home.saxo/en-au/legal/analysis-disclaimer/saxo-analysis-disclaimer)
- Notification on Non-Independent Investment Research (https://www.home.saxo/legal/niird/notification)